🇺🇸 FDA
Patent

US 11357841

Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

granted A61KA61K31/428A61K40/11

Quick answer

US patent 11357841 (Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof) held by Iovance Biotherapeutics, Inc. expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Iovance Biotherapeutics, Inc.
Grant date
Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/428, A61K40/11, A61K40/42, A61K40/4205